Moody’s Upgrades Teva Credit Rating to Investment-Grade Baa3
Moody’s upgraded Teva Pharmaceutical Industries’ corporate credit rating to Baa3 from Ba1, with a stable outlook. The change reflects Teva’s growth strategy, innovative products, expanded pipeline, revenue diversity, improving operating margins, strong free cash flow, and continued debt reduction, with further debt decreases expected over 12 to 18 months. The upgrade follows a Fitch increase in May 2026, strengthening Teva’s credit standing and index eligibility.